Your Body.
Your Results.
Weekly provider check-ins.
Adjustments based on your progress.
Care that evolves with you.
Our Clinical Results
-
27%
1
Average weight loss at 72 weeks for Ivím patients on tirzepatide
-
22%
2
Average weight loss at 68 weeks for Ivím patients on semaglutide
-
22%
3
(vs. 17%)
Average weight loss among Ivím Protocol patients on semaglutide who stayed on treatment vs. completers in a published clinical trial.
Results from two peer-reviewed, retrospective studies of Ivím patients who stayed on treatment. Most used compounded medications. Not head-to-head comparisons. Individual results vary. See study details below.
Patients trust us. The rankings agree.
What patients are saying
4.9
Trustpilot
Rated 4.9 / 5 based on 39,735 reviews on Trustpilot. Showing our 5 star reviews.
Rating and reviews from TrustPilot reflect overall Ivim experience, not any specific medication or outcome.
How It Works
Your Plan
What to Expect
Your Ivím GLP-1 Patient Journey
-
Check In
A quick weekly check-in in the app: how you’re feeling, any side effects, and where your weight and progress stand.
-
Custom Adjustments
Your provider reviews each check-in and fine-tunes your dose or protocol to match how your body is responding.
-
Feel the Difference
Your plan is tuned to you week over week, with the goal of fewer side effects and steadier progress.
The Ivím GLP-1 Program May Be Right for You if…
- You want weight-loss care tailored to your individualized progress.
- You want regular provider check-ins and adjustments as your needs change.
- You want ongoing support beyond receiving a prescription.
- You want a treatment plan that considers your individual goals and experience.
What your program includes
Medicine
ONLY
Your Care Plan
Compounded Semaglutide (GLP-1)
starting at
$65/mo
Compounded Tirzepatide (GLP-1 + GIP)
starting at
$117/mo
+ $75/mo Program Fee
Get StartedIvím offers both FDA-approved medications and compounded medications. Compounded drugs are permitted under federal law but are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality. Prescription required after provider evaluation.
Common Questions
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Bloating or gas
- Decreased appetite or early satiety
Support At Every Step
“For years, the advice was simple: eat less, move more. It’s not that simple. Hunger, metabolism, your body’s set point, those are biological signals, and it’s not always something you can control. When you treat weight the way you’d treat any other medical condition, real change becomes possible.”
¹ 26.5% average total body weight loss at 72 weeks among Ivím tirzepatide patients who stayed on treatment.
² 21.8% average at 68 weeks among Ivím semaglutide patients who stayed on treatment.
³ 21.8% average weight loss at 68 weeks for Ivím semaglutide patients who stayed on treatment under the Ivím Protocol vs. 16.9% for participants who adhered to treatment in a separate published semaglutide trial that included structured diet, exercise, and counseling. Retrospective study with no control group. Differences may reflect care model, population, and study design, and the study does not establish that the Ivím Protocol caused the difference. Not a head-to-head comparison, and not evidence that any medication is more effective than another. More than 90% of Ivím patients used compounded medications.
Results are from two retrospective studies with no control group, published in Obesity Pillars. More than 90% of Ivím patients used compounded medications.
Ivím offers FDA-approved and compounded medications. Compounded drugs are permitted under federal law but are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality. Prescription required after provider evaluation. Individual results vary. Not available in all states. See full safety information. Zepbound® and Wegovy® are registered trademarks of their respective owners.
